Anmeldung erforderlich unter
Various signaling pathways play a role in determining whether tumors form and how they develop and whether they spread to other parts of the body. This includes the Wnt signaling pathway, a subject that MDC researcher Professor Walter Birchmeier has been studying for long time. Cancer can develop if the genes for certain molecules are mutated within the Wnt pathway in such a way that the pathway no longer functions properly. Birchmeier and his team are working on methods to attack these molecules. “We have developed a promising inhibitor called LF3 that blocks tumor growth in mice. Research groups around the world are working on half a dozen similar inhibitors,” reports Birchmeier. One topic discussed in the January lecture will be how LF3 can be used as a monotherapy or combination therapy to treat human cancer patients.
Kinosaal im Zeiss-Großplanetarium
Prenzlauer Allee 80
Prof. Dr. Walter Birchmeier, Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Dr. Marc Nazaré, Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)